无治疗生存期:免疫检查点抑制疗效的新型结局指标——晚期黑色素瘤汇总分析
该研究汇总CheckMate 067和069试验中1077例晚期黑色素瘤患者,提出无治疗生存期(TFS)作为免疫肿瘤药物新型结局指标,定义为ICI方案治疗停止至后续系统治疗启动或死亡之间的时间。36个月时,纳武利尤单抗联合伊匹木单抗的限定平均TFS为11.1个月,长于纳武利尤单抗(4.6个月)和伊匹木单抗(8.7个月),且无毒性TFS亦更长;无论何种治疗,TFS中仅小部分涉及≥3级治疗相关不良事件。
要点
- TFS补充传统生存终点,捕捉ICI停药后无后续治疗的时间。
- 联合组36个月限定平均TFS为11.1个月,优于两个单药组。
- 联合组无毒性TFS长于纳武利尤单抗(差6.0个月)和伊匹木单抗(差1.7个月)。
核心结论
- 晚期黑色素瘤患者接受纳武利尤单抗联合伊匹木单抗的无毒性TFS长于纳武利尤单抗或伊匹木单抗单药。
- 无论何种治疗,TFS中仅小部分涉及≥3级治疗相关不良事件。
研究设计与样本
- 汇总CheckMate 067和069试验中接受纳武利尤单抗和伊匹木单抗单药或联合治疗的晚期黑色素瘤患者数据。
- TFS定义为随机分组至ICI方案治疗停止与至后续系统治疗启动或死亡两条Kaplan-Meier曲线之间的面积。
- TFS通过第三终点(至ICI治疗和毒性均停止的时间)划分为有毒性和无毒性时间,毒性包括持续性和迟发性≥3级TRAE。
- 采用36个月限定平均时间估计各Kaplan-Meier曲线下面积。
主要发现
- 36个月时,1077例启动ICI治疗的患者中无后续治疗启动生存比例分别为纳武利尤单抗联合伊匹木单抗47%、纳武利尤单抗37%、伊匹木单抗15%。
- 限定平均TFS联合组为11.1个月,纳武利尤单抗为4.6个月(差6.5个月,95%CI 5.0至8.0个月),伊匹木单抗为8.7个月(差2.4个月,95%CI 0.8至4.1个月)。
- 限定平均TFS占36个月的比例分别为联合组31%(3%有毒性,28%无毒性)、纳武利尤单抗13%(1%和11%)、伊匹木单抗24%(不足1%和23%)。
- 无毒性TFS联合组较纳武利尤单抗长6.0个月,较伊匹木单抗长1.7个月。
临床怎么用
- TFS可作为传统生存终点的补充,用于评估免疫检查点抑制剂停药后无治疗间期的获益与毒性负担。
- 临床决策中可参考无毒性TFS数据,权衡联合治疗与单药治疗的收益风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points. METHODS: We pooled data from the CheckMate 067 and 069 clinical trials of nivolumab and ipilimumab, as monotherapies or in combination, for patients with advanced melanoma. Treatment-free survival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event end points, each defined from random assignment: time to immune checkpoint inhibitor (ICI) protocol therapy cessation and time to subsequent systemic therapy initiation or death. TFS was partitioned as time with and without toxicity by a third end point, time to cessation of both ICI therapy and toxicity. Toxicity included persistent and late-onset grade 3 or higher TRAEs. The area under each Kaplan-Meier curve was estimated by the 36-month restricted mean time. RESULTS: At 36 months, many of the 1,077 patients who initiated ICI therapy were surviving free of subsequent therapy initiation (47% nivolumab plus ipilimumab, 37% nivolumab, 15% ipilimumab). The restricted mean TFS was longer for nivolumab plus ipilimumab (11.1 months) compared with nivolumab (4.6 months; difference, 6.5 months; 95% CI, 5.0 to 8.0 months) or ipilimumab (8.7 months; difference, 2.4 months; 95% CI, 0.8 to 4.1 months); restricted mean TFS represented 31% (3% with and 28% without toxicity), 13% (1% and 11%), and 24% (less than 1% and 23%) of the 36-month period, respectively, in the three treatment groups. TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months). CONCLUSION: The analysis of TFS between ICI cessation and subsequent therapy initiation revealed longer TFS without toxicity for patients with advanced melanoma who received nivolumab plus ipilimumab compared with nivolumab or ipilimumab. Regardless of treatment, a small proportion of the TFS involved grade 3 or higher TRAEs.
引用
- Regan MM, Werner L, Rao S, et al. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019. PMID: 31498030. doi:10.1200/JCO.19.00345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。